祛瘀消斑胶囊治疗不稳定型心绞痛及对其血浆Fib、DD的影响

目的　观察祛瘀消斑胶囊治疗不稳定型心绞痛及对其血浆Fib和DD水平的影响。方法　对 4 0例不稳定型心绞痛患者随机分为常规西药加祛瘀消斑胶囊治疗组 (治疗组 )和常规西药治疗组 (对照组 ) ,治疗组与对照组各 2 0例。采用相应药物治疗 4周后 ,观察 2组患者的临床疗效、心电图改善及硝酸酯类药物的停减率 ,以及血浆Fib、DD水平变化 ,并进行比较分析。结果　治疗组可显著改善心绞痛症状 ,与对照组比较有显著性差异 (P <0 .0 5 ) ,2组患者心电图改善情况及硝酸酯类药物减停率无显著性差异 (P >0 .0 5 )。治疗组降低Fib、DD水平 ,与对照组比较有显著性差异 (P <0 .0 5 )。 2组均未出现明显不良反应。结论　祛瘀消斑胶囊可显著降低不稳定型心绞痛患者Fib、DD水平 ,联合西药治疗不稳定型心绞痛 ,疗效优于单用西药 ,且安全可靠。     

葛根素注射液治疗不稳定性心绞痛疗效分析

目的　观察葛根素注射液治疗不稳定性心绞痛 (UA)的临床疗效。方法　将 6 8例不稳定性心绞痛患者随机分为治疗组和对照组。对照组 :服用肠溶阿司匹林 10 0～ 30 0mg/d ,10 %葡萄糖 5 0 0ml加 10 %氯化钾 15ml+2 5 %硫酸镁 10ml加普通胰岛素 12U ;治疗组 :在上述基础上加用葛根素注射液 4 0 0mg加 5 %葡萄糖 4 0 0ml。两组均静脉滴注 ,1次 /d ,15d为 1疗程。结果　心绞痛缓解情况 :治疗组总有效率为 85 .3% ,对照组为 6 1.8%(P <0 .0 5 ) ;心电图改善情况 :治疗组总有效率为 82 .4 % ,对照组为 5 5 .9% (P <0 .0 5 )。结论　在常规治疗基础上加用葛根素注射液 ,能有效地控制心绞痛发作。     

Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group

Abstract Epilepsy in high-grade glioma patients is a major concern, mainly as regards indications to treatment and best choice; toxicities, and pharmocokinetic and pharmacodynamic interactions of drugs. All these generally unsolved problems complicate patients’ quality of life and interfere with the evaluation of response criteria in clinical trials. A prospective, multicentre data collection on 132 adult newly diagnosed, histologically proven glioblastomas from 9 Lombardy hospitals collected in the same database during a one-year period was recently published. From this database we report epidemiological and clinical characteristics in epilepsy-symptomatic (31%) glioblastoma patients vs. the group with other presenting symptoms (69%). We analyse demographic and clinico-radiological features, timing of onset and the course of seizures, and modalities of treatment in the two groups of patients. No statistically significant differences were observed between the two groups as regards age, site of lesion(s), extent of surgery and survival in relation to anticonvulsant treatment status or pharmacokinetic properties of drugs.     

A typological model of schizophrenia based on age at onset,sex and familial morbidity

We investigated the age at onset distributions of schizophrenia in men and women and the relationship of age at onset and sex to the familial rates of schizophrenia and manic-depression in data from a Swedish family study of 270 schizophrenic probands. On the logarithmic scale, the age at onset distribution of schizophrenia in both male and female relatives was bimodal, suggesting that broadly defined schizophrenia may be a mixture of 2 (probably related) disorders. The risk of schizophrenia in relatives decreased as a function of the age at onset of the proband, irrespective of the sex of the proband or relative. In contrast, the risk of manic-depression was significantly higher in relatives of female probands with an age at onset in the twenties than in relatives of female probands with earlier or later onset, or in relatives of male probands. This suggests a third disorder related to affective psychosis, with an intermediate age at onset and female preponderance.     

妊娠相关血浆蛋白A水平与不稳定心绞痛患者冠状动脉狭窄病变形态的关系

[目的]探讨不稳定型心绞痛患者妊娠相关血浆蛋白(PAPP-A)水平与高敏C-反应蛋白(hs-CRP)及动脉粥样硬化斑块稳定性的关系.[方法]不稳定型心绞痛组患者42例,稳定型心绞痛组38例.冠状动脉造影前检测PAPP-A和hs-CRP,根据造影结果将冠状动脉病变分为复杂狭窄和光滑狭窄.[结果]稳定型心绞痛组有28例(74%)患者至少有1支血管狭窄≥70%,多于不稳定型心绞痛组的24例(57%),P＜0.05;不稳定型心绞痛组中33例(79%)有1处以上的复杂狭窄,多于稳定型心绞痛组(22例,58%,P＜0.05);PAPP-A与hs-CRP正相关(r=0.44,P＜0.001);不稳定型心绞痛组与稳定型心绞痛组相比,hs-CRP(4.40 mg/L±0.003 mg/L vs 0.48 mg/L±0.016mg/L,P＜0.001)和PAPP-A(18.40×10-3 U/L±0.002×10-3U/Lvs 7.79×10-3 U/L±0.001×10-3 U/L,P＜0.001),差异均有统计学意义;两组中有复杂狭窄者的PAPP-A和hs-CRP水平显著高于无复杂狭窄者.[结论]PAPP-A可作为评估冠状动脉斑块稳定性的血清学指标之一.     

Quality of life on enalapril after acute myocardial infarction

Quality of life was assessed 4–6 months after an acutemyocardial infarction in a randomized double-blind study ofenalapril versus placebo. Quality of life was evaluated usingthe Nottingham Health Profile (NHP), the Physical Symptoms DistressIndex (PSDI), the Work Performance Scale (WPS) and the LifeSatisfaction Index (LSI). The study comprised 36 women (aged46–85 years, mean 68) and 96 males (aged 39–81 years,mean 62). Quality of life did not differ significantly between patientstreated with enalapril versus placebo. The scores were (enalaprilvs placebo, mean± SE): average NHP 15.4 ± 2.3vs 17.1 ± 2.3; PSDI 9.5± 1.0 vs 10.8 ±0.9; WPS 19.8 ± 2.0 vs 19.4 ± 1.4; LSI 24.1 ±1.0 vs 22.5 ±1.4. Men reported a better quality of lifethan women on most assessments, and non-smokers and ex-smokersbetter than smokers. Patients with moderate or severe anginapectoris had a worse quality of life measured by PSDI and NHPthan patients with minimal or no angina pectoris. Patients withcongestive heart failure had a higher PSDI than those without(13.6 ± 1.7 vs 9.4 ± 0.7, P<0.05), while nosignificant differences were observed in the NHP scores. In conclusion, quality of life was similar in enalapril andplacebo- treated patients after an acute myocardial infarction.However, it was reduced in patients with angina pectoris orheart failure and in those who continued smoking.     

葛根素注射液治疗不稳定型心绞痛疗效观察

目的:评价葛根素对不稳定型心绞痛的临床疗效。方法:85例不稳定型心绞痛患者随机分为2组,均常规口服消心痛,同时治疗组葛根素注射液400mg/d,对照组极化液500mL/d。结果:2周后心绞痛缓解,总有效率对照组为70%,治疗组为88.9%,差别不显著(P>0.05);心电图疗效比较,治疗组心肌缺血改善的总有效率71.1%,对照组40%,差别显著(P<0.05);血液流变学比较,治疗组全血粘度、血浆粘度及血小板聚集率均有明显改善(P<0.05),而对照组无此作用。结论:葛根素能有效地改善不稳定型心绞痛患者的症状,抗心肌缺血,降低血液粘度。     

低分子肝素治疗不稳定型心绞痛41例临床观察

目的:探讨低分子肝素治疗不稳定型心绞痛(UA)的临床疗效。方法:对41例不稳定型心绞痛病例,治疗前均常规治疗。在此基础上低分子肝素(体重≤60 kg为5 000 U,体重>60 kg为7 500 U),12 h 1次皮下注射,连用7~14 d,分别于用药前30 min,用药后48 h采血测定活化部分凝血活酶时间(APTT),凝血酶原时间(PT)。结果:显效9例,有效24例,总有效率80.5%。结论:低分子肝素具有高比例的抗因子Xa和抗因子Ⅱa活性,由于其分子量小,与血浆蛋白和内皮细胞结合减少,所以生物利用度高,血浆半衰期长。疗效可取得与肝素同样甚至更高抗凝血酶效果,并且有发生严重出血事件低的优点。     

红花注射液治疗冠心病心绞痛、心肌缺血临床观察

目的:观察红花注射液治疗冠心病心绞痛、心肌缺血的临床疗效。方法:选择126例冠心病心绞痛、心肌缺血的病例,分红花组及丹参组,疗程两周,详细记录治疗前后的临床表现、心电图、血糖、血脂、血液流变学检查的变化。结果:红花、丹参均可明显改善冠心病心肌缺血相应的临床症状和心电图改变,以红花较显著。红花还有降血糖、血脂作用,显著改善血液流变指标。结论:红花注射液是治疗冠心病心绞痛、心肌缺血的理想药物。     

Lifetime and six-month prevalence of mental disorders in the Munich follow-up study

Summary The Lifetime and 6 month DSM-III prevalence rates of mental disorders from an adult general population sample of former West Germany are reported. The most frequent mental disorders (lifetime) from the Munich Follow-up Study were anxiety disorders (13.87%), followed by substance (13.51%) and affective (12.90%) disorders. Within anxiety disorders, simple and social phobia (8.01%) were the most common, followed by agoraphobia (5.47%) and panic disorder (2.39%). Females had about twice the rates of males for affective (18.68% versus 6.42%), anxiety (18.13% versus 9.07%), and somatization disorders (1.60% versus 0.00%); males had about three times the rates of substance disorders (21.23% versus 6.11%) of females. Being widowed and separated/divorced was associated with high rates of major depression. Most disordered subjects had at least two diagnoses (69%). The most frequent comorbidity pattern was anxietyand affective disorders. Simple and social phobia began mostly in childhood or early adolescence, whereas agoraphobia and panic disorder had a later average age of onset. The majority of the cases with both anxiety and depression had depression clearly after the occurrence of anxiety. The DIS-DSM-III findings of our study have been compared with both ICD-9 diagnoses assigned by clinicians independently as well as other epidemiological studies conducted with a comparable methodology.